Pricing Log in Create free account

SELLAS Life Sciences Group, Inc. (SLS) vs Viridian Therapeutics, Inc. (VRDN)

SELLAS Life Sciences Group, Inc. and Viridian Therapeutics, Inc. are both Biotechnology companies. SELLAS Life Sciences Group, Inc. and Viridian Therapeutics, Inc. are of similar size ($2.3B and $2.2B). SELLAS Life Sciences Group, Inc. has the higher net margin (0.00% vs −544.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, SELLAS Life Sciences Group, Inc. leads on 10 and Viridian Therapeutics, Inc. on 5.

Valuation

Metric SLS VRDN Biotechnology median
P/E n/m n/m 8.50
P/S 179.81 28.86 9.71
P/B 13.72 3.64 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 166.67 18.59 9.21
Earnings yield (2.10%) (17.71%) (33.15%)
Free cash flow yield (2.04%) (16.32%) (25.50%)

Profitability

Metric SLS VRDN Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (569.68%) 0.00%
Net margin 0.00% (544.06%) 0.00%
Free cash flow margin 0.00% (471.04%) 0.00%
Return on equity (39.63%) (86.93%) (56.36%)
Return on assets (36.54%) (46.08%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric SLS VRDN Biotechnology median
Revenue growth (TTM) — 23,220.33% 6.02%
EPS growth (last fiscal year) 50.00% (8.14%) 30.26%
Revenue growth, 5-year CAGR — 132.18% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric SLS VRDN Biotechnology median
Debt to equity 0.00 0.37 0.00
Current ratio 18.83 16.95 4.72
Net debt to EBITDA 2.54 2.23 0.96

Dividend

Metric SLS VRDN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric SLS VRDN Biotechnology median
Market cap 2.29b 2.22b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack